Newsletter Subject

An alternative to statins for lowering cholesterol

From

time.com

Email Address

TIME@newsletters.time.com

Sent On

Mon, Mar 6, 2023 09:54 PM

Email Preheader Text

Plus more health news | Email not displaying correctly? By Alice Park Senior Health Correspondent Wh

Plus more health news | Email not displaying correctly? [View it in your browser.]( [Health Matters]( [For those who can’t take statins, there’s hope]( By Alice Park Senior Health Correspondent When it comes to lowering cholesterol, sometimes diet and exercise aren’t enough. Any heart doctor will tell you that statins are their go-to medication for treating stubbornly high cholesterol levels, and for reducing the risk of having a heart attack or other heart event. But up to 30% of people can’t tolerate the side effects like muscle pain—so they either take less-than-optimal doses, or refuse to take the pills at all. For these patients, there's “huge unmet need” for a safe and effective treatment, says Dr. Steven Nissen, a cardiologist at Cleveland Clinic. Nissen spearheaded a new study looking at a drug called bempedoic acid, which could be the alternative that this population has been missing. While it’s already approved for lowering LDL cholesterol, the research found it can also reduce the risk of heart events, a benefit that many doctors had been waiting to see before prescribing the medication. Here’s what the study found: - Bempedoic acid lowers LDL cholesterol by 21%. - The drug reduces the risk of an aggregated measure of heart events, including heart attack and dying of heart disease, by 13%. - It is not associated with the same muscle issues that statins can cause, but it can raise levels of uric acid, so doctors should monitor people with gout who take the drug. [READ MORE]( Share the story What else to read [Current Food Consumption Habits May Add Nearly 1 Degree of Warming by 2100]( By DREW COSTLEY / AP A new study found the majority of emissions come from three major sources: meat from animals like cows, sheep, and goats; dairy; and rice. [Read More »]( [Column: The Beauty of What Happens When Nothing Happens]( By Jenny Odell Jenny Odell explores the wonder of life's most ordinary moments. [Read More »]( [What to Know About Diabetes and the Risk of Silent Heart Attacks]( By Markham Heid Silent heart attacks, which are more common in people with diabetes, don’t cause typical or obvious symptoms. [Read More »]( [Is Seaweed Healthy? Here’s What Experts Say]( By Jamie Ducharme Certain types may be contaminated. (Originally published in 2019.) [Read More »]( [Tuning in to Your Most-Ignored Sense Can Make You Happier]( By Haley Weiss Want to feel happier? Curating your soundscape may benefit your physical and mental health. [Read More »]( ONE LAST READ [The fast-changing world of obesity treatments]( As more people turn to the obesity drug semaglutide (sold under the brand names Ozempic and Wegovy) to lose weight fast, the medical community is concerned that innovations for obesity—a chronic disease with serious health consequences—are being co-opted by the more sales-focused weight-loss market. In the first of a new series for STAT, Elaine Chen and Matthew Herper highlight the tension points and worrying intrusion of marketing and financial priorities in what should be the treatment of a medical condition. [Read More »]( --------------------------------------------------------------- If you were forwarded this and want to sign up to receive it daily, [click here](. Today's newsletter was written by Alice Park and edited by Angela Haupt. [Want more from TIME? Sign up for our other newsletters.]( [Subscribe to TIME]( TIME may receive compensation for some links to products and services in this email. Offers may be subject to change without notice. Connect with TIME via [Facebook]( | [Twitter]( | [Newsletters]( [UNSUBSCRIBE]( [PRIVACY POLICY]( [YOUR CALIFORNIA PRIVACY RIGHTS]( TIME Customer Service, P.O. Box 37508, Boone, IA 50037-0508 Questions? Contact health@time.com Copyright © 2023 TIME USA, LLC. All rights reserved.

Marketing emails from time.com

View More
Sent On

24/05/2024

Sent On

23/05/2024

Sent On

22/05/2024

Sent On

21/05/2024

Sent On

20/05/2024

Sent On

17/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.